Skip to main content
. Author manuscript; available in PMC: 2015 Oct 14.
Published in final edited form as: J Drug Target. 2012 Sep 26;21(1):1–26. doi: 10.3109/1061186X.2012.723213

Figure 7.

Figure 7

Inhibition of metastatic 4T1 mammary adenocarcinoma in the tibia by HPMA copolymer-PTX-ALN conjugate. (A) Chemical structure of the conjugate and the release mechanism of PTX and ALN from the conjugate. (B) Fluorescent images of 4T1 mCherry tumors in the tibia following single, combination of free drugs, and HPMA copolymer-PTX-ALN conjugate treatments on day 15. The treatments were administered i.v. every other day. Scale bar represents 15 mm. (C) Antitumor efficacies of HPMA copolymer-PTX-ALN conjugate (closed squares), free PTX plus ALN (open squares), free PTX (closed circles), and free ALN (open triangles) as compared to vehicle (open circles) and saline (closed triangles) controls. Y-axis represents the fluorescent intensities of the tumors as measured quantitatively by intravital noninvasive fluorescence imaging. The data are presented as mean ± SE. PTX, paclitaxel; ALN, alendronate. Adapted with permission from Miller et al. (2011).